Medical News

RSS

Researcher awarded $1.8M grant to investigate sex differences in anxiety

Anxiety disorders afflict women twice as often as men, but estrogen might not be the reason. Testosterone, though, could be. That is one of the preliminary findings in the lab of Florida State University researcher Mohamed Kabbaj, associate professor in the College of Medicine. He recently was awarded a five-year, $1.8 million grant from the National Institute of Mental Health to investigate the sex differences in anxiety.

2 Sep 2010

Vision and eye health are key to students' classroom ability

Healthy eyes and vision are necessary for school success and an enjoyable life. Parents naturally want to help their children learn and succeed in school and enjoy life. Vision and eye health are key to students' ability to do well in the classroom, on the playground, in sports and when studying at home.

2 Sep 2010

Biodel replaces Linjeta with trade name VIAject

Biodel Inc. announced today that Linjeta™ (pronounced lin-JET-uh) will replace VIAject as the proposed trade name for Biodel's most advanced product candidate.

2 Sep 2010

Thomson Reuters announces acquisition of Healthcare Data Management

Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today announced that it has acquired Healthcare Data Management, Inc. Effective immediately, the company will become part of the Healthcare & Science business of Thomson Reuters. Financial terms of the transaction were not disclosed.

2 Sep 2010

Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints

Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiology's Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with a 28 percent reduction in LDL-cholesterol, compared with an increase of 5 percent for placebo (p<0.001). The trial also met all of its secondary and tertiary endpoints.

2 Sep 2010

HHS Secretary announces grants for patient-centered outcome research

HHS Secretary Kathleen Sebelius today announced three sets of grants and cooperative agreements totaling nearly $17 million for patient-centered outcomes research (PCOR), or research that compares treatments and strategies to improve health outcomes for patients.

2 Sep 2010

TGen researchers use RNAi-based screening to study Ewing's sarcoma

The first study of Ewing's sarcoma that screened hundreds of genes based on how they affect cell growth has identified two potential anti-cancer drug targets, according to a scientific paper by the Translational Genomics Research Institute published this month in the journal Molecular Cancer.

2 Sep 2010

QRxPharma announces interim analysis of MoxDuo IR clinical program

QRxPharma announced today a successful interim analysis of its final MoxDuo IR pivotal Phase 3 study required for New Drug Application (NDA) submission.

2 Sep 2010

Skills for Health publishes English regional briefings on skills and labour market environment

New resources to help health sector employers understand and respond to the fast-changing regional skills and labour market environment have been published by Skills for Health, the UK's Skills Council for healthcare.

2 Sep 2010

Study: Preemptive surgery may help prevent cancer for some women

A study published in the Journal of the American Medical Association suggests that women with a gene mutation linked to breast and ovarian cancer face lower risks of developing such cancer after receiving mastectomies or having their ovaries removed, The Wall Street Journal reports.

2 Sep 2010

HIV-infected children who receive HAART require revaccination: Researchers

HIV-infected children receiving highly active antiretroviral therapy may require revaccination to maintain immunity against preventable diseases. There remains no standard or official recommendation on revaccination of children receiving HAART, an effective intervention in reducing morbidity and mortality in HIV-infected children.

2 Sep 2010

Cellerant Therapeutics signs contract with BARDA to develop CLT-008 therapy for ARS

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has signed a contract valued at up to $153 million over five years with the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, to develop CLT-008, a cellular therapy for the treatment of Acute Radiation Syndrome (ARS).

2 Sep 2010

Increased physical activity can reduce cardiovascular risk in children from lower socio-educational background

A year-long study into the effects of increased physical activity at school has shown that children's fitness levels and body composition do improve with daily participation in sport - and particularly so for children from deprived backgrounds. Obesity among children and young people continues to rise across Europe and brings with it the very real risk of increased blood pressure, higher blood-fat values and impaired glucose tolerance.

2 Sep 2010

Promega to provide FuGENE HD Transfection Reagent throughout life science market

Promega Corporation announces it will provide FuGENE HD Transfection Reagent throughout the life science market. The comprehensive, direct use offering from Promega means any life scientist can utilize FuGENE technology with no licensing requirements. FuGENE HD enables the transfection of DNA into many cell types with high efficiency and little-to-no toxicity.

2 Sep 2010

Anvil Group receives contract to safeguard health care in Sierra Leone

UK based security company, The Anvil Group, has been awarded a contract by a long-standing client to safeguard the health and security of its international workforce during a construction project in Sierra Leone.

2 Sep 2010

Inhibitex completes INX-189 Phase1a trial for HCV

Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.

2 Sep 2010

WHO proposes creation of African Public Health Emergency Fund, strategy to reduce alcohol use in Africa

During the 60th session of the Africa Committee of the WHO on Monday, Luis Sambo, regional director of the WHO for Africa, proposed the creation of a public health emergency fund to provide financial support to African countries in emergency situations, Agencia AngolaPress reports (8/30).

2 Sep 2010

Accumetrics secures $24 million in capital infusion

Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced today that it has completed its capital financing efforts, the first round of which was announced in the Fall of 2009.

2 Sep 2010

Nabi Biopharmaceuticals, Diosynth sign long-term commercial manufacturing agreement

Nabi Biopharmaceuticals announced today that it has entered into a long-term commercial manufacturing agreement with Diosynth RTP, Inc. for the manufacture of Drug Substance integral to the production of NicVAX, Nabi's innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse.

2 Sep 2010

ThromboGenics second microplasmin Phase III trial for non-surgical treatment of VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its primary endpoint.

2 Sep 2010

Medical News

Researcher awarded $1.8M grant to investigate sex differences in anxiety

Vision and eye health are key to students' classroom ability

Biodel replaces Linjeta with trade name VIAject

Thomson Reuters announces acquisition of Healthcare Data Management

Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints

HHS Secretary announces grants for patient-centered outcome research

TGen researchers use RNAi-based screening to study Ewing's sarcoma

QRxPharma announces interim analysis of MoxDuo IR clinical program

Skills for Health publishes English regional briefings on skills and labour market environment

Study: Preemptive surgery may help prevent cancer for some women

HIV-infected children who receive HAART require revaccination: Researchers

Cellerant Therapeutics signs contract with BARDA to develop CLT-008 therapy for ARS

Increased physical activity can reduce cardiovascular risk in children from lower socio-educational background

Promega to provide FuGENE HD Transfection Reagent throughout life science market

Anvil Group receives contract to safeguard health care in Sierra Leone

Inhibitex completes INX-189 Phase1a trial for HCV

WHO proposes creation of African Public Health Emergency Fund, strategy to reduce alcohol use in Africa

Accumetrics secures $24 million in capital infusion

Nabi Biopharmaceuticals, Diosynth sign long-term commercial manufacturing agreement

ThromboGenics second microplasmin Phase III trial for non-surgical treatment of VMA meets primary endpoint

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News